Sibold William John sold $1.4M of MDGL

Sibold William John (President and CEO) sold 2,500 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $547.30 ($542.75–$555.05, $1.37M total) across 10 trades on 2026-07-20.

Original reporting
SEC EDGAR · Sibold William John
Published Jul 21, 2026, 1:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDGL
Neutral
medium confidence
Mentioned
$MDGL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale totaling $1,368,253.46 across 10 trades on 2026-07-20, with holdings after the sale of 209,329 shares and no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may monitor for sentiment impact, but the filing alone does not provide new clinical, regulatory, or financial information.

03

What to watch

The article provides sale price range and share count but no context on tax, option exercises, or prior planned schedules, which can materially change interpretation.

Relevance 6/10Novelty 4/10Timing: Filed 2026-07-20 after-hours, reflecting insider sale executed on 2026-07-20.

Background

The article is a SEC Form 4 insider transaction disclosure for Madrigal Pharmaceuticals, Inc. (MDGL).

Company-level read

Ticker impact

$MDGLNeutralMedium confidence
Context

Madrigal Pharmaceuticals CEO William John Sibold sold about $1.37M of MDGL shares in an open-market Form 4 transaction on 2026-07-20.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider sale (open-market, no 10b5-1 plan stated) with no accompanying company-specific operational or financial update in the text.

Market effects

Minimal, as this is company-specific insider activity with no sector-wide regulatory or clinical signal provided.

None indicated.

None indicated.

Counterpoint

CEO sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative outlook.

Key entities

  • Madrigal Pharmaceuticals, Inc.

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • Sibold William John

    President and CEO reporting an open-market sale of MDGL shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.